Skip to main content
HCAT
NASDAQ Technology

Health Catalyst Reports $111M Q1 Net Loss, $95.5M Goodwill Impairment; Announces Further 9% Workforce Reduction

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$1.57
Mkt Cap
$101.549M
52W Low
$0.955
52W High
$4.74
Market data snapshot near publication time

summarizeSummary

Health Catalyst reported a significantly widened Q1 net loss of $111 million, including a $95.5 million goodwill impairment, alongside an 11% revenue decline and plans for a further 9% workforce reduction.


check_boxKey Events

  • Massive Net Loss

    Reported a net loss of $111.0 million for Q1 2026, a significant increase from $23.7 million in Q1 2025.

  • Substantial Goodwill Impairment

    Incurred a $95.5 million non-cash goodwill impairment charge in Q1 2026, primarily due to declines in stock price and market capitalization.

  • Revenue Decline

    Total revenue decreased by 11% year-over-year to $70.8 million, with professional services revenue down 24% and technology revenue down 4%.

  • Further Workforce Reduction Planned

    Authorized 'Project Nexus,' a 9% global workforce reduction in Q2 2026, eliminating approximately 100 positions, with expected charges of at least $4.0 million.


auto_awesomeAnalysis

Health Catalyst reported a net loss of $111.0 million for Q1 2026, a substantial increase from $23.7 million in Q1 2025. This significant loss includes a $95.5 million goodwill impairment charge, reflecting a major write-down of asset values due to declines in stock price and market capitalization. Total revenue decreased by 11% year-over-year to $70.8 million, driven by a 24% drop in professional services revenue and a 4% decline in technology revenue. The company also announced 'Project Nexus,' a subsequent event involving a 9% workforce reduction in Q2 2026, following previous restructuring plans. These financial results and operational changes highlight severe ongoing challenges, including significant ARR at risk from platform migrations and a deteriorating balance sheet, which could impact the company's long-term viability.

At the time of this filing, HCAT was trading at $1.57 on NASDAQ in the Technology sector, with a market capitalization of approximately $101.5M. The 52-week trading range was $0.96 to $4.74. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed HCAT - Latest Insights

HCAT
May 11, 2026, 5:03 PM EDT
Filing Type: 10-Q
Importance Score:
9
HCAT
May 11, 2026, 4:12 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
HCAT
May 11, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
HCAT
Apr 30, 2026, 5:19 PM EDT
Filing Type: 10-K/A
Importance Score:
8
HCAT
Apr 30, 2026, 9:22 AM EDT
Filing Type: 8-K
Importance Score:
7
HCAT
Apr 27, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
8
HCAT
Apr 02, 2026, 5:56 PM EDT
Filing Type: 8-K
Importance Score:
7
HCAT
Mar 12, 2026, 4:58 PM EDT
Filing Type: 10-K
Importance Score:
9
HCAT
Mar 12, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
HCAT
Mar 12, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8